Gilead Sciences Presents New Data On Twice-Yearly Lenacapavir For HIV Prevention
14/7 17:05
(RTTNews) - Gilead Sciences, Inc. (GILD) Monday announced that Gilead researchers and collaborators will present new Phase 3 Purpose trial data at IAS 2025 showing that twice-yearly lenacapavir (Yeztugo) was effective and well tolerated among a broad range of populations who need...